2023-09-28T10:40:53-05:00 2022-12-31 221478099 COHNREZNICK LLP 7501 WISCONSIN AVENUE SUITE 400E BETHESDA MD 20814 990 2022-01-01 311667995 CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY CONQ 5714831700 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 LINDA A JENSEN EVP & CFO 5714831700 2023-09-26 1 LINDA JENSEN 999009999 0 LORI ROTHE YOKOBOSKY CPA P01273422 3016529100 2023-09-25 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z CONQUER CANCER & CONQUER CANCER FDTN NANCY DALY MS MPH 2318 MILL RD STE 800 ALEXANDRIA VA 22314 36852780 0 X WWW.CONQUER.ORG X 1999 VA TO ACCELERATE BREAKTHROUGHS IN LIFESAVING RESEARCH AND EMPOWER PEOPLE EVERYWHERE TO CONQUER CANCER. 20 19 0 285 0 0 21747229 31125188 312459 363476 2617495 1837688 -35881 -192660 24641302 33133692 19181199 20648632 0 0 0 0 60000 257693 7101948 9164357 11982603 28405556 32888928 -3764254 244764 109850269 98117170 10347798 14432042 99502471 83685128 X CONQUER CANCER FUNDS RESEARCH FOR EVERY TYPE OF CANCER TO BENEFIT EVERY PATIENT, EVERYWHERE. WORKING IN COLLABORATION WITH A GLOBAL NETWORK OF TOP SCIENTISTS AND CLINICIANS, AND LEADING ADVOCACY AND RESEARCH ORGANIZATIONS, CONQUER CANCER DRAWS (CONTINUED IN SCHEDULE O) ON THE PASSION AND EXPERTISE OF THE CANCER PROFESSIONALS WHO ARE MEMBERS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO). CONQUER CANCER WORKS TO HELP CREATE A WORLD WHERE CANCER IS PREVENTED OR CURED AND EVERY SURVIVOR IS HEALTHY. 0 0 17585949 14125671 SEE SCHEDULE O:RESEARCH: RESEARCH IS HOW WE CONQUER CANCER. IT MEANS EVERYTHING, FROM UNDERSTANDING HOW CANCER IMPACTS CERTAIN PEOPLE TO FINDING GROUNDBREAKING NEW WAYS TO TREAT CANCER. THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $158 MILLION IN CANCER RESEARCH GRANTS TO OVER 2,600 RECIPIENTS IN 80 COUNTRIES. HIGHLIGHTS OF 2022 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE:RESEARCH PROFESSORSHIP (RP): $500,000 PROVIDED ONE (1) FIVE-YEAR AWARD TO AN OUTSTANDING RESEARCHER WHO HAS MADE, AND IS CONTINUING TO MAKE, SIGNIFICANT CONTRIBUTIONS IN BREAST CANCER RESEARCH AND WILL DEDICATE THEIR TIME IN TRAINING FUTURE BREAST CANCER RESEARCHERS. THIS PROFESSORSHIP IS DESIGNED WITH THE PRIMARY GOAL OF INCREASING DIVERSITY IN THE LEADERSHIP OF THE ONCOLOGY WORKFORCE AND CANCER RESEARCH. *ADVANCED CLINICAL RESEARCH AWARD (ACRA): $900,000 PROVIDED TWO (2) THREE-YEAR AWARDS TO SUPPORT PHYSICIAN-SCIENTISTS COMMITTED TO PERFORMING ORIGINAL, CLINICAL CANCER RESEARCH WITH A PATIENT-ORIENTED FOCUS. BOTH AWARDS SUPPORTED DIVERSITY/INCLUSION, FOCUSING ON BREAST CANCER. *CAREER DEVELOPMENT AWARD (CDA): $4,400,000 PROVIDED TWENTY-TWO (22) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH TO CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS. *YOUNG INVESTIGATOR AWARD (YIA): $4,820,000 PROVIDED NINETY-SIX (96) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY PROVIDING FUNDS TO PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT. *GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD: $291,500 PROVIDED SIX (6) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS TO ENCOURAGE AND PROMOTE QUALITY RESEARCH IN GLOBAL ONCOLOGY AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS.THIS IS A MENTORED AWARD AND THE RESEARCH PROJECT IS CONDUCTED UNDER THE GUIDANCE OF A SCIENTIFIC MENTOR. *INTERNATIONAL INNOVATION GRANT: $94,838 PROVIDED FIVE (5) ONE-YEAR AWARDS IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO POTENTIALLY DISCOVERING INTERVENTIONS TRANSFERABLE TO CLINICAL CARE IN OTHER LOW OR MIDDLE RESOURCE COUNTRY SETTINGS.THROUGH ITS EVERYGRANT PROGRAM, CONQUER CANCER UTILIZES ITS EXPERTISE IN GRANTS ADMINISTRATION AND PROGRAM MANAGEMENT TO COLLABORATE WITH OTHER ORGANIZATIONS TO DEVELOP AND DELIVER PROGRAMS THAT MAKE A DIFFERENCE TO CANCER CARE TEAMS AND PATIENTS EVERYWHERE. 5744479 5619139 SEE SCHEDULE O:PROFESSIONAL EDUCATION: CONQUER CANCER SUPPORTS THE EFFORTS OF ASCO TO PROVIDE EDUCATION PROGRAMS IN THE US AND INTERNATIONALLY WHICH PROMOTE THE VITAL EXCHANGE OF IDEAS AND LATEST DEVELOPMENTS THAT LEAD TO WORLD-CLASS CARE, EVERYWHERE. FUNDS FROM CONQUER CANCER ARE USED TO SUPPORT ASCO'S SCIENTIFIC AND EDUCATIONAL PROGRAMS THROUGH BOTH MEETINGS AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC PROGRAMS SUPPORTED BY CONQUER CANCER AND PRESENTED TO THE PUBLIC IN 2022 INCLUDE THE FOLLOWING: * ASCO ANNUAL MEETING: THE ASCO ANNUAL MEETING IS CONSIDERED THE PREMIER EDUCATIONAL AND SCIENTIFIC EVENT IN THE ONCOLOGY COMMUNITY WITH MORE THAN 42,000 PARTICIPANTS WORLDWIDE IN 2022. THE ANNUAL MEETING PROVIDES A FORUM TO JOIN GLOBAL CANCER EXPERTS AND DISCOVER THE LATEST INNOVATIONS IN CANCER RESEARCH AND EDUCATION WHILE ADDRESSING THE NEED FOR EVERY PATIENT TO RECEIVE THE HIGHEST QUALITY CANCER CARE AVAILABLE. *GASTROINTESTINAL CANCERS (GI) SYMPOSIUM: THIS IS THE PREMIER MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETING. THE GI SYMPOSIUM GIVES HEALTHCARE PROVIDERS ACROSS MULTIPLE DISCIPLINES AND PROFESSIONS THE OPPORTUNITY TO RECEIVE CRITICAL UPDATES AND RECOMMENDATIONS TO IMPROVE THE CARE OF PATIENTS WITH GI CANCERS. *GENITOURINARY CANCERS (GU) SYMPOSIUM: THIS IS THE PREEMINENT GENITOURINARY ONCOLOGY EVENT, ADDRESSING THE MULTIDISCIPLINARY NEEDS OF PHYSICIANS AND OTHER MEMBERS OF THE CANCER CARE AND RESEARCH COMMUNITY WHO DIAGNOSE, TREAT, AND STUDY GENITOURINARY MALIGNANCIES. THE GU SYMPOSIUM PROVIDES THE LATEST STRATEGIES IN SCREENING, DIAGNOSIS, TREATMENT, MANAGEMENT AND CONTROVERSIES IN THE FIELD OF GENITOURINARY CANCERS. *QUALITY CARE SYMPOSIUM: THIS IS AN UNPARALLELED OPPORTUNITY TO LEVERAGE THE MOST UP-TO-DATE SCIENCE AND DISCOVER PROVEN STRATEGIES AND TOOLS CRITICAL TO MAKING KEY DECISIONS THAT CAN REDUCE DISPARITIES IN CARE FOR EVERY PATIENT, EVERY DAY, EVERYWHERE. *MERIT AWARDS: 240,000 PROVIDED TWO HUNDRED THIRTY-SIX (236) MERIT AWARDS PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AT ASCO SCIENTIFIC MEETINGS AND DISEASE SPECIFIC SYMPOSIA. *MEDICAL STUDENT ROTATION FOR UNDERREPRESENTED POPULATIONS (MSR): $238,000 PROVIDED TWENTY-EIGHT (28) MEDICAL STUDENT ROTATIONS. THE MSR PROVIDES A 4-WEEK CLINICAL OR CLINICAL RESEARCH ROTATION FOR U.S. MEDICAL STUDENTS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE WHO ARE INTERESTED IN PURSUING ONCOLOGY AS A CAREER. 996592 903822 363476 SEE SCHEDULE O:QUALITY & ACCESS TO CARE: REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH QUALITY CANCER CARE IS AVAILABLE TO EVERYONE. CONQUER CANCER IS KEENLY AWARE OF THE POTENTIALLY FATAL DIVIDE BETWEEN THOSE WITH ACCESS TO THE FRUITS OF RESEARCH AND TIMELY CARE AND THOSE WITHOUT. WE SEEK TO CONFRONT THESE DISPARITIES AND IMPROVE THE OUTLOOK FOR EVERY PERSON TOUCHED BY CANCER BY SUPPORTING PROGRAMS THAT INCREASE ACCESS TO CARE IN ALL COMMUNITIES, INCLUDING THOSE THAT ARE UNDERSERVED. 24327020 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 1 1 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 0 1 125 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 20 19 0 0 0 1 0 1 1 1 1 0 0 1 1 1 1 1 1 0 0 0 AL AR CA FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NC OR PA RI SC TN UT VA WV WI NY X X LINDA JENSEN EVP CFO 5714831300 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 CLIFFORD A HUDIS MD EXECUTIVE VICE CHAIR 6.50 31.00 X X 0 930020 22875 AMY C PETERSON MD SECRETARY 1.00 X X 0 0 0 ALEXANDER W CASDIN TREASURER 1.00 X X 0 0 0 KATHRYN BEAL BOARD MEMBER 1.00 X 0 0 0 RICHARD J BOXER MD BOARD MEMBER 1.00 X 0 0 0 RICCARDO BRAGLIA BOARD MEMBER 1.00 X 0 0 0 SUSAN L COHN MD BOARD MEMBER 1.00 X 0 0 0 LAWRENCE H EINHORN MD BOARD MEMBER 1.00 X 0 0 0 RAJ MANTENA RPH BOARD MEMBER 1.00 X 0 0 0 THOMAS A MARSLAND MD BOARD MEMBER 1.00 X 0 0 0 ROBERT J MAYER MD BOARD MEMBER 1.00 X 0 0 0 GERALD J MCDOUGALL BOARD MEMBER 1.00 X 0 0 0 ANNE MOORE MD BOARD MEMBER 1.00 X 0 0 0 W CHARLES PENLEY MD BOARD MEMBER 1.00 X 0 0 0 THOMAS G ROBERTS JR MD BOARD MEMBER 1.00 X 0 0 0 STEVEN T ROSEN MD BOARD MEMBER 1.00 X 0 0 0 ALEXANDRA SHAPIRO BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 SANDRA SWAIN MD BOARD MEMBER 1.00 X 0 0 0 MARGARET A TEMPERO MD BOARD MEMBER 1.00 X 0 0 0 DEANNA B VAN GESTEL BOARD MEMBER 1.00 X 0 0 0 LINDA JENSEN CFO & EXECUTIVE VP 1.00 36.50 X 0 431666 39119 NANCY DALY MS MPH CEO & EXECUTIVE VP 36.50 1.00 X 0 477749 39092 0 1839435 101086 0 0 1 0 TRUE NORTH INC 12 WEST 27TH STREET 13TH FLOOR NEW YORK NY 10001 MEDIA BUY SOLICITATIONS 1515499 FAIRCOM NY 630 3RD AVENUE 12TH FLOOR NEW YORK NY 10017 DIRECT MAIL SOLICITATIONS 945473 2 3954 1269000 1676299 3514500 24661435 37345 31125188 GRANTS EXPERTISE 900099 363476 363476 363476 1978770 1978770 3385346 3526428 -141082 -141082 -141082 0 1676299 192660 -192660 -192660 33133692 363476 0 1645028 18880794 18880794 413000 413000 1354838 1354838 7148827 2180556 522307 4445964 3000 3000 68500 68500 257693 257693 40300 40300 1932897 996540 539287 397070 17235 17235 1296393 230178 69916 996299 632003 5440 21994 604569 490964 123029 107243 260692 296735 124837 60410 111488 54949 14808 29203 10938 MISC 800 800 32888928 24327020 1459960 7101948 5062629 9023972 5040333 5402813 164928 130103 99582379 83560282 109850269 98117170 401810 160281 4926484 3179628 3600008 8376287 1419496 2715846 10347798 14432042 X 47032655 34722323 52469816 48962805 99502471 83685128 109850269 98117170 244764 -16062107 0 X X 0 1 X 1 0 X 31933505 27209762 34795083 22059688 31125188 147123226 31933505 27209762 34795083 22059688 31125188 147123226 19090227 128032999 719934 2667684 1592952 1980450 1978770 8939790 269300 276883 546183 64871 106173 171044 156780243 825935 0.81660 0.81730 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 39078370 2822771 -5342139 1276921 35282081 35692561 1997125 2783059 1394375 39078370 27740161 6504115 2786765 1338480 35692561 17571755 8235901 2772005 839500 27740161 17114411 2133374 -974377 711653 17561755 1.00000 0 0 0 DUE TO ASCO 2715846 2715846 X 17223945 -16062107 -16062107 33286052 40300 -192660 -152360 33133692 33041288 0 33041288 40300 -192660 -152360 32888928 PART V, LINE 4: PERMANENTLY RESTRICTED NET ASSETS OF DONOR-RESTRICTED ENDOWMENT FUNDS ARE PRESERVED, ABSENT EXPLICIT DIRECTION FROM THE DONOR. INTEREST FROM THE PERMANENTLY RESTRICTED FUNDS IS INTENDED TO FUND FUTURE RESEARCH AND/OR EDUCATIONAL AWARDS. PART X, LINE 2: CONQUER CANCER IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE ("IRC"). IT HAS BEEN GRANTED PUBLIC CHARITY STATUS BY THE INTERNAL REVENUE SERVICE (THE "IRS") AND HAS BEEN CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION. IN 2022 AND 2021, CONQUER CANCER GENERATED NO UNRELATED BUSINESS INCOME AND ACCORDINGLY HAD RELATED BUSINESS INCOME TAX OF $0 IN 2022 AND 2021, RESPECTIVELY. CONQUER CANCER ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH THE INCOME TAX TOPIC OF THE FINANCIAL ACCOUNTING STANDARDS BOARD ACCOUNTING STANDARDS CODIFICATION ("FASB ASC"). CONQUER CANCER BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. GENERALLY, CONQUER CANCER IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE 2019. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSE -192,660. PART XII, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSE -192,660. PART V, LINES 1A-AG ENDOWMENT FUNDS ARE BASED ON GAAP AND AGREE TO THE RESTRICTED FUNDS ON THE AUDITED FINANCIAL STATEMENTS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES AWARDS & GRANTS 273000 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 PROGRAM SERVICES AWARDS & GRANTS 372000 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 PROGRAM SERVICES AWARDS & GRANTS 200000 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 0 0 PROGRAM SERVICES AWARDS & GRANTS 78890 SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 0 0 PROGRAM SERVICES AWARDS & GRANTS 220948 SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, 0 0 PROGRAM SERVICES AWARDS & GRANTS 200000 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 PROGRAM SERVICES AWARDS & GRANTS 10000 0 0 0 0 0 0 1354838 0 1354838 SOUTH ASIA INTERNATIONAL INNOVATION GRANT (IIG) 15000 WIRE 0 SUB-SAHARAN AFRICA INTERNATIONAL INNOVATION GRANT (IIG) 19948 WIRE 0 SOUTH ASIA INTERNATIONAL INNOVATION GRANT (IIG) 19890 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) CAREER DEVELOPMENT AWARD SPECIAL COMPETITIONS 200000 WIRE 0 SOUTH AMERICA CAREER DEVELOPMENT AWARD (CDA) 200000 WIRE 0 SOUTH ASIA INTERNATIONAL INNOVATION GRANT (IIG) 20000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) YOUNG INVESTIGATOR AWARD SPECIAL COMPETITIONS 50000 WIRE 0 SUB-SAHARAN AFRICA CAREER DEVELOPMENT AWARD (CDA) 200000 WIRE 0 NORTH AMERICA CAREER DEVELOPMENT AWARD (CDA) 200000 WIRE 0 SOUTH ASIA INTERNATIONAL INNOVATION GRANT (IIG) 20000 WIRE 0 MIDDLE EAST AND NORTH AFRICA CONQUER CANCER-ISRAEL CANCER RESEARCH FUND CAREER DEVELOPMENT AWARD 200000 WIRE 0 NORTH AMERICA YOUNG INVESTIGATOR AWARD (YIA) 150000 WIRE 0 0 12 ANNUAL MEETING MERIT AWARD EAST ASIA AND THE PACIFIC 7 7000 WIRE ANNUAL MEETING MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 16 16000 WIRE ANNUAL MEETING MERIT AWARD NORTH AMERICA 14 16000 WIRE ANNUAL MEETING MERIT AWARD SOUTH ASIA 4 4000 WIRE ANNUAL MEETING MERIT AWARD SUB-SAHARAN AFRICA 1 1000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD EAST ASIA AND THE PACIFIC 2 2000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 4 4000 WIRE GASTROINTESTINAL CANCERS SYMPOSIUM MERIT AWARD NORTH AMERICA 3 3000 WIRE GENITOURINARY CANCERS SYMPOSIUM MERIT AWARD EAST ASIA AND THE PACIFIC 1 1000 WIRE GENITOURINARY CANCERS SYMPOSIUM MERIT AWARD EUROPE (INCLUDING ICELAND & GREENLAND) 3 3000 WIRE GENITOURINARY CANCERS SYMPOSIUM MERIT AWARD NORTH AMERICA 2 2000 WIRE ASCO QUALITY CARE SYMPOSIUM AWARD NORTH AMERICA 1 1000 WIRE 0 0 0 0 0 0 PART I, LINE 2: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL EARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CONQUER CANCER REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENT WITH THE APPROVED BUDGET. PART I, LINE 3: THE ACCRUAL METHOD IS USED TO ACCOUNT FOR FOREIGN EXPENDITURES. PART III ACCOUNTING METHOD: X X X X X X 1 FAIRCOM NEW YORK 12 WEST 27TH ST 13TH FLOOR NEW YORK NY 10001 DIRECT MAIL SOLICITATIONS 0 546685 208889 337796 TRUENORTH 515 MADISON AVE STE 8083 NEW YORK NY 10022 FUNDRAISING COUNSEL 0 0 154000 -154000 546685 362889 183796 AL AK AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI CONQUER CANCER DINNER 690750 690750 408 179797 INTEGRA CONNECT (OCTOBER) 413850 413850 154 12301 9 571699 571699 1676299 1676299 562 192098 192660 -192660 SCHEDULE G, PART I, LINE 2B, COLUMN (V) FAIRCOM NY- CONQUER CANCER PAYS A RETAINER FEE FOR FUNDRAISING SERVICES, INCLUDING STRATEGY, COPY WRITING, LIST RECOMMENDATIONS, DATA ANALYSIS, ETC. 1 BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 770303411 741613878 501(C)(3) 48369 0 YIA BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON MA 02116 042312909 501(C)(3) 100000 0 YIA CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES CA 90048 951644600 501(C)(3) 200000 0 CDA THE CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH STREET PHILADELPHIA PA 19146 231352166 501(C)(3) 50000 0 YIA COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 630 WEST 168TH STREET BOX 49 NEW YORK NJ 100327922 135598093 501(C)(3) 250000 0 ASCO REGISTRY RESEARCH GRANT, CDA, YIA DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 400000 0 CDA,YIA DUKE UNIVERSITY 2200 W MAIN ST STE 820 DURHAM NC 27705 560532129 501(C)(3) 50000 0 MSR, ACRA EMORY UNIVERSITY 1599 CLIFTON ROAD 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 600000 0 CDA H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 200000 0 ASCO REGISTRY RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501(C)(3) 50000 0 CDA, GO YIA JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 150000 0 YIA JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB STE 117 BALTIMORE MD 212051832 520595110 501(C)(3) 300000 0 CDA THE GENERAL HOSPITAL CORP DBA MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 041564655 501(C)(3) 700000 0 CAREER PATHWAY GRANT IN SYMPTON MANAGEMENT, YIA MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 559050001 416011702 501(C)(3) 100000 0 CDA, YIA RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 35 STATE STREET ALBANY NY 12207 141368361 501(C)(3) 100000 0 YIA SEATTLE CHILDREN'S HOSPITAL 1900 NINTH AVENUE M/S 818-S SEATTLE WA 981011309 910564748 501(C)(3) 50000 0 YIA ST JUDE CHILDREN'S RESEARCH HOSPITAL INC 262 DANNY THOMAS PLACE MEMPHIS TN 38105 620646012 501(C)(3) 293955 0 CDA, GO YIA LELAND STANFORD JUNIOR UNIVERSITY 455 BROADWAY REDWOOD CITY CA 940633126 941156365 501(C)(3) 50000 0 YIA UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 753909020 756002868 GOVT ENTITY 950000 0 YIA UNIVERSITY OF CALIFORNIA SAN FRANCISCO 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94143 946036493 GOVT ENTITY 550000 0 CDA, YIA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DR STE 2200 CB 1350 CHAPEL HILL NC 275991350 566001393 GOVT ENTITY 150000 0 ACRA, CDA, YIA UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET 5TH FL FRANKLIN BLDG PHILADELPHIA PA 191046205 231352685 GOVT ENTITY 150000 0 YIA UNIVERSITY OF ROCHESTER 518 HYLAN BUILDING - BOX 270140 ROCHESTER NY 14627 160743209 501(C)(3) 200000 0 YIA UNIVERSITY OF SOUTH FLORIDA 4019 E FOWLER AVENUE SUITE 100 TAMPA FL 33617 593102112 GOVT ENTITY 100000 0 YIA UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE BOX 359472 SEATTLE WA 98195 916001537 GOVT ENTITY 99176 0 CAREER PATHWAY GRANT IN SYMPTON MANAGEMENT VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVENUE SUITE 970 NASHVILLE TN 37203 352528741 501(C)(3) 150000 0 CDA, YIA WASHINGTON UNIVERSITY IN ST LOUIS CAMPUS BOX 1054 ONE BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501(C)(3) 300000 0 YIA YALE UNIVERSITY 25 SCIENCE PARK NEW HAVEN CT 06510 060646973 501(C)(3) 100000 0 YIA ATRIUM HEALTH'S LEVINE CANCER INSTITUTE PO BOX 32861 CHARLOTTE NC 28232 566060481 501(C)(3) 50000 0 YIA LOMA LINDA UNIVERSITY 11145 ANDERSON ST 205 LOMA LINDA CA 92350 951816009 501(C)(3) 200000 0 CDA MEMORIAL SLOAN-KETTERING CANCER CENTER 1725 YORK AVE NEW YORK NY 10065 131924236 501(C)(3) 1250000 0 CDA, YIA OHIO STATE UNIVERSITY 901 WOODY HAYES DR COLUMBUS OH 43210 316025986 GOVT ENTITY 800000 0 ARCA, CDA, YIA THE METHODIST HOSPITAL RESEARCH INSTITUTE 6565 FANIN ST GB 240 HOUSTON TX 77030 870721923 501(C)(3) 50000 0 YIA THE ROCKEFELLER UNIVERSITY 1230 YORK AVE NEW YORK NY 10065 131624158 501(C)(3) 50000 0 YIA THE UNIVERSITY OF ARIZONA 1303 E UNIVERSITY BLVD TUCSON AZ 85719 742622689 GOVT ENTITY 30000 0 ASCO REGISTRY RESEARCH GRANT THE UNIVERSITY OF CHICAGO 6054 S DREXEL AVE CHICAGO IL 60637 362177139 501(C)(3) 150000 0 YIA THOMAS JEFFERSON UNIVERSITY 1101 MARKET ST STE 2004 PHILADELPHIA PA 19107 231352651 501(C)(3) 50000 0 YIA UNIVERSITY OF ALABAMA AT BIRMINGHAM 701 20TH S ST BIRMINGHAM AL 35294 636005396 GOVT ENTITY 250000 0 CDA, YIA UNIVERSITY OF CALIFORNIA LOS ANGELES 110 WESTWOOD PLAZA LOS ANGELES CA 90095 956006143 GOVT ENTITY 50000 0 YIA REGENTS OF THE UNIVERSITY OF COLORADO 1800 N GRANT ST STE 400 DENVER CO 80203 846000555 501(C)(3) 50000 0 YIA UNIVERSITY OF IOWA 105 JESSUP HALL IOWA CITY IA 52242 426004813 GOVT ENTITY 152606 0 CAREER PATHWAY GRANTS IN SYMPTOM MANAGEMENT UNIVERSITY OF NEBRASKA MEDICAL CENTER 988145 NEBRASKA MEDICAL CENTER OMAHA NE 68198 911858433 501(C)(3) 50000 0 YIA UNIVERSITY OF PITTSBURGH 116 ATWOOD ST STE 201 PITTSBURGH PA 15213 250965591 501(C)(3) 215000 0 CAREER PATHWAY GRANTS IN SYMPTOM MANAGEMENT, YIA AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 136180380 501(C)(3) 9233468 0 CHARITABLE ASSISTANCE 44 0 MERIT AWARDS 183 186000 MEDICAL STUDENT ROTATION AWARDS 26 215000 ANNUAL MEETING RESEARCH AWARDS 8 12000 PART I, LINE 2: CONQUER CANCER GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CONQUER CANCER'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES AND SPONSORING INSTITUTIONS ARE REQUIRED TO SIGN A GRANT AGREEMENT THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE TO CONQUER CANCER AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT BY THE END OF THE PROJECT PERIOD OR TO MEET THE PROPOSED TIME SCHEDULES. CONQUER CANCER MAY APPROVE UP TO A MAXIMUM OF THREE NO-COST EXTENSIONS OF SIX MONTH INCREMENTS. GRANTEES ARE REQUIRED TO NOTIFY CONQUER CANCER IF THEY PLAN TO LEAVE THEIR SPONSORING INSTITUTION DURING THE COURSE OF THEIR GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO CONQUER CANCER'S REVIEW AND APPROVAL. CONQUER CANCER REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (EXPENDITURE REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND AN EXPENDITURE REPORT ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF EACH GRANT BUDGET PERIOD. CONQUER CANCER REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, A FINAL PROGRESS REPORT AND A FINAL EXPENDITURE REPORT ARE REQUIRED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CONQUER CANCER REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED TO CONQUER CANCER. GRANTS ARE ADMINISTRATIVELY CLOSED AFTER RECEIPT OF THE FINAL PROGRESS REPORT, FINAL EXPENDITURE REPORT, ANY REMAINING BALANCE ON THE GRANT, AND AFTER CONQUER CANCER'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS OF THE GRANT HAVE BEEN MET. CONQUER CANCER RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENTLY WITH THE APPROVED BUDGET. 0 0 0 0 0 0 0 0 0 CLIFFORD A HUDIS MD EXECUTIVE VICE CHAIR 0 928832 0 0 0 1188 0 22875 0 0 0 952895 0 0 NANCY DALY MS MPH CEO & EXECUTIVE VP 0 466561 0 10000 0 1188 0 22875 0 16217 0 516841 0 0 LINDA JENSEN CFO & EXECUTIVE VP 0 419380 0 10000 0 2286 0 22875 0 16244 0 470785 0 0 PART I, LINE 3 COMPENSATION IS ESTABLISHED BY A RELATED ORGANIZATION, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC. (ASCO). THE METHODS USED BY ASCO TO DETERMINE COMPENSATION ARE: COMPENSATION COMMITTEE; INDEPENDENT COMPENSATION CONSULTANT; FORMS 990 OF OTHER ORGANIZATIONS, WRITTEN EMPLOYMENT CONTRACT; COMPENSATION STUDY OR SURVEY; AND APPROVAL BY BOARD OR COMPENSATION COMMITTEE. X 5 37345 FMV 0 0 1 0 PART I, COLUMN (B): THE NUMBER ABOVE REPRESENTS THE NUMBER OF CONTRIBUTIONS MADE, NOT THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION A, LINE 5 IN 2022, CONQUER CANCER DISCOVERED THAT ONE OF ITS VENDORS HAD BEEN THE VICTIM OF A SCHEME IN WHICH A THIRD PARTY BAD ACTOR HAD HACKED INTO THE VENDOR'S EMAIL SYSTEMS. THE BAD ACTOR USED ITS ACCESS TO THE VENDOR'S SYSTEMS TO DIRECT CONQUER CANCER TO SEND PAYMENTS DUE TO THE VENDOR TO ANOTHER BANKING ACCOUNT. $268,071.54 WAS INITIALLY DIVERTED, ALTHOUGH A SIGNIFICANT PORTION OF THE DIVERTED FUNDS WERE RECOVERED BY CONQUER CANCER'S BANK. CONQUER CANCER FILED A POLICE REPORT, AS WELL AS A REPORT WITH THE FBI, AND IS WORKING WITH ITS INSURANCE CARRIERS ON ADDITIONAL RECOVERY. FORM 990, PART VI, SECTION A, LINE 7A CONQUER CANCER DOES NOT HAVE MEMBERS. DIRECTORS OF CONQUER CANCER ARE APPOINTED AND SUBJECT TO REMOVAL BY THE BOARD OF DIRECTORS OF ASCO, EXCEPT FOR DIRECTORS SERVING EX-OFFICIO. FORM 990, PART VI, SECTION A, LINE 7B THE BOARD OF DIRECTORS OF CONQUER CANCER MAY VOTE TO AMEND OR REPEAL THE BYLAWS OF CONQUER CANCER, BUT THE BOARD OF DIRECTORS OF ASCO MUST APPROVE AN AMENDMENT OR REPEAL OF THE BYLAWS TO BE EFFECTIVE. CONQUER CANCER MAY NOT AMEND ITS ARTICLES OF INCORPORATION WITHOUT PROVIDING TO ASCO WRITTEN NOTICE OF THE PROPOSED AMENDMENT AT LEAST THIRTY (30) DAYS IN ADVANCE. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE TAX RETURN, INCLUDING ALL APPLICABLE SCHEDULES, WAS PROVIDED TO THE BOARD OF DIRECTORS, CHIEF FINANCIAL OFFICER AND GENERAL COUNSEL FOR REVIEW AND COMMENT PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C CONQUER CANCER MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL CONQUER CANCER STAFF, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G., SPOUSE, DEPENDENT CHILDREN). UNDER CONQUER CANCER'S POLICIES, COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS,CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE, AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. CONQUER CANCER'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, WHEN CONQUER CANCER IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY "INTERESTED PERSON" (I.E., A CONQUER CANCER DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE CHIEF EXECUTIVE OFFICER OF CONQUER CANCER, THE EXECUTIVE VICE CHAIR OF CONQUER CANCER, AND THE CHIEF FINANCIAL OFFICER OF CONQUER CANCER SERVE AS EMPLOYEES OF ASCO. INFORMATION REGARDING THEIR COMPENSATION AND THE PROCESS FOR DETERMINING THEIR COMPENSATION, INCLUDING REVIEW AND APPROVAL BY INDEPENDENT PERSONS, COMPARABILITY DATA, AND CONTEMPORANEOUS SUBSTANTIATION OF THE DELIBERATION AND DECISION, ARE DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER STAFF ARE EMPLOYEES OF ASCO WHO ARE LEASED TO CONQUER CANCER. APPLICABLE INFORMATION REGARDING THEIR COMPENSATION IS DESCRIBED IN THE IRS FORM 990 OF ASCO. CONQUER CANCER DOES NOT PAY COMPENSATION TO THESE INDIVIDUALS. FORM 990, PART VI, SECTION C, LINE 19 CONQUER CANCER'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. CONQUER CANCER'S ARTICLES OF INCORPORATION ARE ALSO AVAILABLE TO THE PUBLIC THROUGH THE VIRGINIA STATE CORPORATION COMMISSION. CONFLICT OF INTEREST POLICIES AND STANDARDS ARE POSTED ON CONQUER CANCER'S WEBSITE. THE ANNUAL REPORT OF CONQUER CANCER IS POSTED ON CONQUER CANCER'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM CONQUER CANCER UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS OF CONQUER CANCER ARE POSTED ON CONQUER CANCER'S WEBSITE. PART XII, LINE 2C THE AUDIT OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 136180380 EDUCATION NY 501(C)(3) LINE 10 N/A 0 ASCO ASSOCIATION 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 833561639 MEMBER SERVICES VA 501(C)(6) ASCO 0 ASCO ASSOCIATION PAC 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 844213157 PAC VA 527 ASCO ASSOCIATION 0 0 1 1 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0 0 ASCO ASSOCIATION Q 94012 COST